H. Lundbeck A/S: Depressive Disorder, Major trials

The registry lists 36 Depressive Disorder, Major studies with H. Lundbeck A/S as lead sponsor. 0 are open to participants now and 20 have results posted.

Phase 2 7Phase 3 21Phase 4 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of AgeTerminatedNCT02871297Phase 3Results posted
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)CompletedNCT02709746Phase 3Results posted
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)CompletedNCT02709655Phase 3Results posted
• Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant TreatmentCompletedNCT02400346Phase 3Results posted
• Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive DisorderTerminatedNCT01944969Phase 3Results posted
• Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant TherapyCompletedNCT01942785Phase 3Results posted
• Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentCompletedNCT01838681Phase 3Results posted
• Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentTerminatedNCT01837797Phase 3Results posted
• Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian CountriesCompletedNCT01571453Phase 3Results posted
• A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous MedicationCompletedNCT01488071Phase 3Results posted
• Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive DisorderCompletedNCT01422213Phase 3Results posted
• Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT01323478Phase 3Results posted
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in AdultsCompletedNCT01140906Phase 3Results posted
• Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in AdultsCompletedNCT00839423Phase 2Results posted
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly PatientsCompletedNCT00811252Phase 3Results posted
• Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive DisorderCompletedNCT00807248Phase 2Results posted
• Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT00761306Phase 2Results posted
• Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT00694304Phase 3Results posted
• Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive DisorderCompletedNCT00635219Phase 3Results posted
• Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive EpisodesCompletedNCT00596817Phase 3Results posted
• Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From DepressionCompletedNCT04448431Phase 4
• Vortioxetine in Patients With Depression and Early DementiaCompletedNCT04294654Phase 4
• Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in IndiaCompletedNCT04288895Phase 4
• Study With Vortioxetine on Emotional Functioning in Patients With DepressionCompletedNCT03835715Phase 4
• Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With DepressionCompletedNCT03766867Phase 2
• Real-life Effectiveness of Vortioxetine in DepressionCompletedNCT03555136
• Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of AgeCompletedNCT03108625Phase 3
• Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive DisorderCompletedNCT02919501Phase 2
• Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking VortioxetineCompletedNCT02332954Phase 4
• Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive DisorderCompletedNCT02279966Phase 3
• Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive DisorderCompletedNCT02279953Phase 3
• Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive DisorderCompletedNCT02272517Phase 3
• A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive DisorderCompletedNCT01427439
• Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive DisorderCompletedNCT01148472Phase 4
• Efficacy and Safety of Lu AA34893 in Patients With Major Depressive DisorderTerminatedNCT00766870Phase 2
• Dose-finding Study With Lu AA24530 in Major Depressive DisorderCompletedNCT00599911Phase 2